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Abstract 
Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) is a unifocal 
mucosal or cutaneous ulcer that is histologically characterized by proliferating 
EBV-positive atypical B cells. While EBVMCU demonstrates a histology similar to that 
of EBV-positive diffuse large B-cell lymphoma (DLBCL), their clinical behavior differs. 
Thus, characterizing distinguishing features of EBVMCU and EBV-positive DLBCL is 
critical. To identify unique characteristics between EBVMCU and lymphoma, we 
analyzed the clinicopathological and genetic features of 34 Japanese patients with 
EBVMCU and compared them to those of 24 EBV-positive DLBCL patients and 25 
EBV-negative DLBCL patients. All patients with EBVMCU had localized ulcerative 
lesions, and 31 patients (91%) were using immunosuppressants, such as methotrexate 
(MTX) or hydroxycarbamide. All patients that were followed up with exhibited good 
prognosis following immunosuppressant reduction or chemotherapy. Additionally, 17 
EBV-positive DLBCL patients, and 15 EBV-negative DLBCL patients, received 
chemotherapy (P < 0.001, P < 0.001, respectively). Our data showed that EBVMCU 
did not increase indicators associated with lymphoma prognosis, such as soluble 
interleukin 2 receptor (sIL-2R) and lactate dehydrogenase (LDH) compared to those in 
the EBV-positive DLBCL or EBV-negative DLBCL groups (sIL-2R, P < 0.001, P = 
0.025; LDH, P = 0.018, P = 0.038, respectively). However, histologically, EBVMCU 
exhibited EBV-positive, variable-sized, atypical B-cell proliferation. Thus, EBVMCU 
was histologically classified as: (1) polymorphous; (2) large cell-rich; (3) classic 
Hodgkin lymphoma-like; and (4) mucosa-associated lymphoid tissue lymphoma-like. 
Moreover, genetic analysis showed that immunoglobin heavy chain (IGH) gene 
rearrangement did not differ significantly between EBVMCU and EBV-positive 
DLBCL (44% vs. 32%; P = 0.377), or between EBVMCU and EBV-negative DLBCL 
(44% vs. 58%; P = 0.280). Therefore, it is difficult to distinguish EBVMCU from 
EBV-positive DLBCL using only pathological and genetic findings, suggesting that 
clinical information is important in accurately distinguishing between EBVMCU and 
EBV-positive DLBCL. 
Introduction 
Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) was first 
described as a distinct clinicopathological entity in 2010, when Dojcinov et al. reported 
26 patients with ulcerative lesions confined to the oropharynx, skin and gastrointestinal 
tract (1). These patients were immunosuppressed, with either age-related 
immunosenescence or by iatrogenic immunosuppression. Subsequently, EBVMCU has 
been reported in patients with primary immunodeficiencies (2-4), solid organ or bone 
marrow transplant recipients (5-8) and human immunodeficiency virus/acquired 
immune deficiency syndrome (HIV/AIDS) (9). In general, patients with EBVMCU 
exhibit good prognosis with spontaneous regression or complete remission following 
reduced immunosuppression (10). EBVMCU was later described by the World Health 
Organization as a new disease concept, which was distinct from lymphomas, and 
recognized as a specific type of iatrogenic immunodeficiency-associated 
lymphoproliferative disorders (LPD) (11). 
Histologically, EBVMCU is characterized by EBV-positive, polymorphous, atypical 
proliferating B cells that can resemble Hodgkin and Reed-Sternberg (HRS) cells. These 
atypical cells accompany dense polymorphic inflammatory cell infiltration, such as 
plasma cells, eosinophils and histiocytes. The EBV-positive cells demonstrate B-cell 
immunophenotypes, i.e., CD20 expression. Thus, it is difficult to distinguish EBVMCU 
from lymphomas (1, 10, 11). To clarify clinical, pathological and molecular 
characteristics between EBVMCU and diffuse large B-cell lymphoma (DLBCL), we 
examined clinicopathological features and gene rearrangements for immunoglobulin 
heavy chain (IGH) and T cell receptor (TCR). 
  
Materials and methods 
Patient samples 
We analyzed the clinicopathological features of 34 patients with EBV-positive 
mucocutaneous ulcers. All cases were retrieved from the surgical pathology 
consultation files of the Department of Pathology at Okayama University between 2009 
to 2019. Of the 34 EBVMCU patients, 33 were biopsy specimens and one was a 
resected specimen. We excluded patients with a history of lymphoma; other lesions 
identified by radiation diagnosis i.e., positron emission tomography and computed 
tomography; as well as samples with inappropriate material for analysis via polymerase 
chain reaction (PCR), such as microtissues or necrotic tissues. We also selected 24 
patients with EBV-positive DLBCL and 25 patients with EBV-negative DLBCL as 
control groups, all of which were not on active therapy by immunosuppressants. All 
EBVMCU, EBV-positive DLBCL and EBV-negative DLBCL cases were reviewed 
independently by three pathologists (TI, TY and YS) to confirm the diagnosis and 
immunophenotype. 
 This study was approved by the Institutional Review Board of Okayama University.  
 
 
Histological examination and in situ hybridization 
Specimens were fixed in 10% formaldehyde and embedded in paraffin. Serial, 3-μm 
thick sections were cut from paraffin-embedded tissue blocks for staining procedures. 
Sections were stained with hematoxylin and eosin or were immunohistochemically 
stained with antibodies specific for CD3 (clone: LN10, 1:200; Novocastra Laboratories, 
Ltd., Newcastle upon Tyne, UK), CD5 (clone: 4C7, 1:100; Novocastra Laboratories, 
Ltd.), CD10 (clone: 56C6, 1:100; Novocastra Laboratories, Ltd.), CD15 (clone: Carb-3, 
1:50; DAKO, Glostrup, Denmark), CD20 (clone: L26, 1:100; DAKO), CD30 (clone: 
Ber-H2, 1:40; DAKO), CD79a (clone: JCB117, 1:50; DAKO) and Ki-67 (clone: MIB-1, 
1:2500; DAKO). Staining was performed using automated Bond Max Stainer (Leica 
Biosystems, Wetzlar, Germany) according to manufacturer’s instructions. 
Immunoglobulin kappa or lambda light chains (Igκ or Igλ) were detected by in situ 
hybridization with Kappa and Lamda probes (PB0645, PB0669, respectively; Leica 
Biosystems) using automated Bond Max Stainer (Leica Biosystems). EBV was detected 
by in situ hybridization for EBV-encoded small RNA (EBER, fluorescein-conjugated 
oligonucleotide probe: PB0589; Leica Biosystems) using automated Bond Max Stainer 
(Leica Biosystems). 
 
PCR assays of the IGH locus and TCR gene rearrangements 
Tissue sections were scraped from the lesion and placed in AmpliTaq Gold Buffer 
(Applied Biosystems, Inc., Foster City, CA, USA). DNA was extracted by incubating at 
94°C for 45 minutes in an automated GeneAmp PCR System 9700 thermocycler 
(Applied Biosystems, Inc.). DNA was quantified using NanoDrop ND1000 
spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). All gene 
rearrangement analyses were performed by a method that has been previously described 
(12). All primers were purchased from Sigma-Aldrich (Sigma-Aldrich Japan, Tokyo, 
Japan). PCR products were analyzed using ABI PRISM 310 Genetic Analyzer with 
GeneScan Analysis and GeneMapper software (Applied Biosystems, Inc.) (12). For 
IGH rearrangements, DNA was amplified using Framework Region II and III primers. 
JH consensus primer was fluorescently labeled (6-Carboxyfluorescein) (12). For 
EBVMCU cases, additional IGK rearrangement assays were performed to investigate 
rearrangements involving Vk loci. IGH, IGK, IGL and TCR gene rearrangements were 
analyzed and evaluated using BIOMED-2 protocol (12). The results of fragment 
analysis were interpreted as monoclonal, oligoclonal, or polyclonal. If the exponential 
amplification of PCR is a single high peak, cell samples are monoclonal. In the same 
way, two high peaks indicate oligoclonal samples and multiple peaks indicate 




Statistical differences between EBVMCU, EBV-positive DLBDL and EBV-negative 
DLBCL were determined using the Mann-Whitney test and the Chi-squared (χ2 ) test. P 
< 0.05 was considered statistically significant. All statistical analyses were performed 





The clinical features of 34 EBVMCU patients have been summarized in Table 1. The 
median age of the 34 cases was 73 years (range: 54 – 91 years). The male-to-female 
ratio was 0.89:1. A total of 30 patients were treated with MTX for rheumatoid arthritis 
(RA) or polymyalgia rheumatica. One patient was treated for polycythemia using 
hydroxycarbamide. Further, one patient was treated with tacrolimus (TAC) as an 
immunosuppressant in addition to MTX. Another three patients were not on active 
immunosuppression therapy. The median soluble interleukin 2 receptor (sIL-2R) value 
was 652 U/mL (range: 263 – 2786 U/mL, n = 22). The median lactate dehydrogenase 
(LDH) value was 212 U/mL (range: 151 – 397 U/mL, n = 28) and the median serum 
albumin (SA) value was 3.8 g/dL (range: 2.9 – 4.6 g/dL, n = 25). All patients had 
mucosal or cutaneous ulcers with no apparent mass lesions [gingiva (n = 13, 38%), 
tonsil (n = 7, 21%), pharynx (n = 3, 9%), tongue (n = 2, 6%), oral cavity (n = 3, 9%), 
buccal mucosa (n = 1, 3%), nasal cavity (n = 2, 6%) and skin (n = 3, 9%)] (Figure 1) . 
Multiple ulcers were identified in the oral mucosa or bilateral tonsils in three cases. 
(Case No.4, 13, 15) Patients did not have lesions in other regions. 
After the diagnosis, MTX or hydroxycarbamide was discontinued in 29 patients. In 28 
patients (97%), lesion remission occurred and treatment was discontinued. No 
additional chemotherapy was found to be necessary. Only one patient did not present 
with resolved lesions. This patient then received chemotherapy (R-THP-COP; 
combined rituximab, pirarubicin, cyclophosphamide, vincristine and prednisolone) and 
had complete remission (Case No.8). Since the disease concept of EBVMCU was not 
established at the time of diagnosis, one patient was treated with chemotherapy without 
reducing MTX (Case No.4). For the same reason, another one patient with no history of 
immunosuppression was treated with chemotherapy (R-CHOP; combined rituximab, 
cyclophosphamide, vincristine, Adriamycin and prednisolone) and was in complete 
remission (Case No.7). 
Among the 24 patients with EBV-positive DLBCL, the median age was 77 years 
(range: 33 – 94 years) and the male-to-female ratio was 3:1. One patient had a nodular 
skin lesion with no ulcer and another 23 patients had no mucocutaneous lesions. The 
median sIL-2R value was 4585 U/mL (range: 460 – 18600 U/mL, n = 22), the median 
LDH value was 265 U/mL (range: 146 – 903 U/mL, n = 22) and the median SA value 
was 3.3 g/dL (range: 2.0 – 4.9 g/dL, n = 17). Of the 17 patients who received 
chemotherapy, four exhibited complete remission after treatment and eight patients died 
of the primary disease. 
Among the 25 patients with EBV-negative DLBCL, the median age was 73 years 
(range: 33 – 92 years) and the male-to-female ratio was 1.5:1. The median sIL-2R value 
was 2392 U/mL (range: 199 – 18832 U/mL, n = 25), the median LDH value was 277 
U/mL (range 142 – 1576 U/mL, n = 25) and the median SA value was 3.9 g/dL (range: 
2.8 – 4.4 g/dL, n = 20). Of the 15 patients who received chemotherapy, nine exhibited 
complete remission after chemotherapy and three died of the primary disease. We have 
shown the clinical features of EBVMCU, EBV-positive DLBCL and EBV-negative 
DLBCL in Table 2 and Figure 2. The median follow-up durations were 20.4 months, 
30.9 months and 30.3 months for patients with EBVMCU, EBV-positive DLBCL and 
EBV-negative DLBCL, respectively. 
 
Histological and immunohistochemical features 
EBVMCU presented with localized mucosal or cutaneous ulcers. The disease is 
characterized by the presence of atypical lymphoid cells of various sizes and is 
accompanied by dense polymorphic infiltration with variable inflammatory cells such as 
plasma cells, histiocytes and granulocytes. The large cells often resemble HRS cells. 
Angioinvasion was observed in 14 of the 34 EBVMCU patients (Figure 3). Atypical 
lymphoid cells did not infiltrate into the epithelium. Accordingly, we classified 
EBVMCU into the following morphological types: 
Polymorphous 
Polymorphous refers to cases with various small to large atypical EBER-positive 
lymphoid cells. Some cases include few HRS-like cells. Atypical lymphoid cells are 
found in various densities such as dense and scattered. This type is often associated with 
necrosis and angioinvasion. Of the 34 EBVMCU patients, 20 cases (59%) were 
classified as polymorphous (Figure 4). 
Large cell-rich  
The atypical lymphoid cells primarily consist of large and monomorphic, with dense 
proliferation observed similar to those in monomorphic proliferation DLBCL. Seven of 
the 34 EBVMCU patients (21%) were classified as large cell-rich (Figure 5). 
Classic Hodgkin lymphoma (CHL)-like 
This type consists of many HRS cells and various sized atypical lymphoid cells. The 
aggregation of CD30-positive HRS cells is highlighted similar to those in CHL, 
however EBER-positive small to medium sized atypical lymphoid cells also are seen. 
Some cases also contain epithelioid granulomas or eosinophil infiltration. Of the 34 
EBVMCU patients, 4 cases (12%) were classified as CHL-like (Figure 6). Interestingly, 
two cases of these cases exhibited spontaneous regression. This clinical outcome 
differed from the CHL type of other iatrogenic immunodeficiency-associated LPD (13). 
Mucosa-associated lymphoid tissue (MALT) lymphoma-like 
The atypical lymphoid cells show small to medium sized, centrocytic-like features, 
and/or plasmacytic features, which proliferate in the expanded interfollicular zone. One 
case showed mature plasmacytic differentiation with Russell bodies (Figure 7). All 
cases exhibited light chain restriction and had no lymphoepithelial lesions. Of the 34 
EBVMCU patients, three (9%) were classified as MALT lymphoma-like, two of which 
exhibited spontaneous regression. 
 
Immunohistochemistry 
Positive CD3, CD5, CD10, CD20, CD30 and EBER staining was observed in 0% 
(0/34), 0% (0/12), 10% (1/10), 94% (32/34), 92% (11/12) and 100% (34/34) of the 
atypical lymphoid cells in samples, respectively. Two cases were negative for CD20 
and positive for CD79a. 
Atypical B cells exhibited diffuse or scattered infiltration primarily in subepithelial 
tissue. The background consisted mainly of numerous CD3-positive T cells (Figure 4). 
Similarly, in EBV-positive DLBCL, B cells exhibited a wide range of infiltration 
patterns, from diffuse to scattered.CD3-positive T cells did not clearly form a rosette 
around HRS-like cells. 




Table 3 shows the IGH and TCR rearrangements. In patients with EBVMCU, IGH 
(FR2) PCR analysis was successful in 23 cases and monoclonality was detected in four 
patients (17%). IGH (FR3) PCR analysis was successful in 32 cases and monoclonality 
was detected in 13 patients (41%). In summary, IGH rearrangement was detected in 14 
of the 32 patients (44%). TCR rearrangement was detected in nine of the 28 patient 
cases (32%) that were successfully analyzed by PCR. 
We also investigated light chain rearrangements in EBVMCU. As summarized in 
Table 3, IGK monoclonality was detected in ten of the 25 patients (40%) that were 
successfully assayed for IGK by PCR. Of the seven patients with a successful IGL PCR 
analysis, six (86%) showed an IGL rearrangement. 
Table 3 also shows the results of EBV-positive DLBCL and EBV-negative DLBCL 
cases: EBV-positive DLBCL [IGH: monoclonal/oligoclonal (32%, n = 7), polyclonal 
(68%, n = 15); TCR: n = 20, monoclonal/oligoclonal (10%, n = 2) and polyclonal (90%, 
n = 18)]. EBV-negative DLBCL [IGH: monoclonal/oligoclonal (58%, n = 14), 
polyclonal (42%, n = 10); TCR: n = 20, monoclonal/oligoclonal (15%, n = 3) and 
polyclonal (85%, n = 17)]. 
We then compared the IGH rearrangement in EBVMCU, EBV-positive DLBCL and 
EBV-negative DLBCL, and observed that the IGH rearrangement occurred in 44% 
(14/32), 32% (7/22, P = 0.377) and 58% (14/24, P = 0.280) of the cases, respectively. In 
addition, the TCR rearrangement occurred in 32% (9/28), 10% (2/21, P = 0.060) and 
15% (3/20, P = 0.176) of the cases, respectively. 
  
Discussion 
EBVMCU was first described by Dojcinov et al. in 2010 as a distinct 
clinicopathological entity occurring in immunosuppressed patients demonstrating either 
age-related immunosenescence or iatrogenic immunosuppression (1). Before EBVMCU 
was defined, several reports described mucosal ulcerations occurring as a side effect of 
MTX therapy. However, most of these reports did not perform histological evaluation 
(14). Soon after, EBVMCU was reported in patients with primary immunodeficiencies 
(3, 4), solid organ or bone marrow transplant recipients (5-8) and in patients with 
HIV/AIDS (9). EBVMCU was later described as a new disease type by the World 
Health Organization (11). Here, it should be noted that other disease concepts, such as 
MTX-LPD and EBV-positive marginal zone lymphoma (MZL), overlap with 
EBVMCU (15, 16). Given that most EBVMCU do not require chemotherapy, we 
believe that prioritizing diagnosis of EBVMCU over other 
immunodeficiency-associated LPD will benefit those patients with overlapping disease 
concepts. 
In this study, we investigated the clinicopathological differences as well as the IGH 
and TCR gene rearrangements between EBVMCU and DLBCL. Overall, more female 
patients developed EBVMCU, which may be related to the fact that diseases involved in 
RA tend to be more common in women (17). Our data showed that EBVMCU did not 
increase lymphoma prognosis indicators, such as sIL-2R and LDH (18), compared to 
that in EBV-positive DLBCL and EBV-negative DLBCL. Since lesions in EBVMCU 
are local, patients tend to show relatively low sIL-2R or LDH levels. Particularly, the 
level of sIL-2R exhibited significant differences (Figure 2). However, it is necessary 
that the clinical significance of LDH and sIL-2R levels be ultimately entrusted to each 
clinician. Of note, many EBVMCU patients had autoimmune diseases that caused 
chronic inflammation. Therefore, hemoglobin and SA values were not found to differ 
significantly between EBVMCU and EBV-positive DLBCL, EBVMCU and 
EBV-negative DLBCL cases. 
In this study, one patient with age-related EBVMCU received chemotherapy. The 
lesions in 24 patients with iatrogenic EBVMCU achieved complete or partial remission 
after discontinuation of the immunosuppression therapy. One patient suffered relapse 
after hydroxycarbamide re-administration. These results indicate that EBVMCU relapse 
is associated with repeated immunosuppression. Given that patients with EBVMCU 
generally reach complete remission, we suggest that further long-term observations may 
be required. Moreover, even if the ulcers improved, EBVMCU often destroys normal 
tissues, making clinical complete remission difficult to determine.  
Herein, we classified EBVMCU into four morphological types as described above. It 
is necessary to be aware of this histological variety in EBVMCU to accurately 
distinguish it from lymphomas. 
In the best of our knowledge, MALT lymphoma-like EBVMCU has not been 
previously reported. However, some reports have proposed EBV-positive MZL 
occurring in immunosuppressed patients (15, 16). These reports found that most patients 
had clinically indolent disease with response to reduced immune suppression. In this 
regard we consider the disease concept of EBV-positive MZL to overlap with MALT 
lymphoma-like EBVMCU. However, clinical findings differ between MALT 
lymphoma-like EBVMCU, and EBV-positive MZL. For instance, in previous reports, 
EBV-positive MZL was described as being extraoral with non-ulcerative tumoral 
lesions, while MALT lymphoma-like EBVMCU is characterized by oral and ulcerative 
lesions. Considering the clinical findings, MALT lymphoma-like EBVMCU should be 
distinguished from EBV-positive MZL. 
Few previous reports have investigated the clonality in EBVMCU. Dojcinov et al. first 
reported that 38% of the cases exhibited IGH rearrangements and 31% exhibited TCR 
rearrangements, however, there were no control groups included in this study (1). In 
2011, relatively low frequency of the clonal IGH rearrangements were described in 
patients with age-related EBVMCU compared to those in EBV-positive DLBCL and 
EBV-negative DLBCL (19). 
In the current study, the clonal IGH rearrangements in EBVMCU and EBV-positive 
DLBCL patients tended to occur less frequently than in patients with EBV-negative 
DLBCL (44%, 32%, 58%). However, there were no significant differences between the 
three groups. Thus, IGH rearrangements are not useful for distinguishing between 
EBVMCU and DLBCL. 
Previous reports have shown that most EBV-positive cases exhibit polyclonal 
multiplication (13, 20). EBV-positive DLBCL showed a relatively low frequency of 
clonal IGH rearrangements, although this may be due to possible false-negative PCR 
results, which can be attributed to the presence of EBV-positive blastocytes. Since 
EBV-positive cases tend to have a low IGH monoclonality, the IGH rearrangement was 
also found to be of low frequency in EBV-positive DLBCL (13, 20). 
A previous report also demonstrated that serum CD8-positive T cells were elevated 
after MTX reduction (21). Meanwhile, another report showed that B-cell post-transplant 
LPD were associated with clonal expansion of CD8-positive T cells (22). Thus, we 
considered that EBVMCU also may be associated with T cell clonal expansion as a 
result of reduced immune surveillance. Another report showed the presence of TCR 
beta chain variable restriction in more than half of the elderly patients (23). In our study, 
clonal TCR rearrangements in EBVMCU tended to occur more frequently than in 
EBV-positive DLBCL and EBV-negative DLBCL cases (32%, 10%, 15%). Our data, 
therefore, supports that T cell clonal expansion in EBVMCU is associated with 
immunosuppression, as with other immunodeficiency-associated LPD (21, 22). In 
addition, T cell clonality does not indicate EBVMCU or the possibility of T cell 
lymphoma. 
While T cell clonality was observed, the HRS-like cells may not have an immune 
evasion mechanism. For example, previous reports have shown the presence of PD-L1 
in most EBV-positive DLBCL cases (24-26), however, PD-L1 was absent in all 
EBVMCU cases (27). These results suggest that there may be no immune evasion 
mechanism as seen in EBV-positive DLBCL. 
In summary, EBVMCU in the Japanese population represents a wide pathological 
spectrum, similar to that exhibited by neoplastic lesions, that includes polymorphic LPD, 
sometimes, DLBCL, CHL and MALT lymphoma. Furthermore, the IGH rearrangement 
in EBVMCU has been confirmed, though at a lower frequency than that observed in 
EBV-negative DLBCL. Regardless of the histological feuture and the IGH 
rearrangement, EBVMCU shows good prognosis. 
In our study, EBVMCU was histologically and genetically difficult to distinguish from 
lymphoma, suggesting that the collection of clinical information, particularly that 
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Figure legends 
Figure 1. Macroscopic findings of Epstein-Barr virus-positive mucocutaneous ulcer in 
buccal mucosa (Case No. 31). The ulcer appeared while the patient was undergoing 
methotrexate treatment (A). After reducing methotrexate, the lesion spontaneously 
disappeared (B). 
 
Figure 2. Comparison of sIL-2R and LDH in EBVMCU, EBV-positive DLBCL and 
EBV-negative DLBCL 
(A) Differences and distribution of sIL-2R in EBVMCU, EBV-positive DLBCL and 
EBV-negative DLBCL. (B) Differences and distribution of LDH in EBVMCU, 
EBV-positive DLBCL and EBV-negative DLBCL. Box plot explanation: upper 
horizontal line of box, 75th percentile; lower horizontal line of box, 25th percentile; 
horizontal bar within box, median; upper horizontal bar outside box, 95th percentile; 
lower horizontal bar outside box, 5th percentile. 
 
Figure 3. Pathologic findings of angioinvasion in EBVMCU. 
Various sized atypical lymphoid cells infiltrating the wall of blood vessels. These 
atypical lymphoid cells are positive for EBER. (HE, EBER, ×400) 
 
Figure 4. Pathologic findings of polymorphous EBVMCU 
(A) A gingival ulcer of a 71-year-old-female undergoing methotrexate treatment (Case 
No. 28). Atypical polymorphous lymphoid cells with few HRS-like cells are seen with 
granulocytes (×400). Atypical lymphoid cells infiltrated and destroyed the blood vessel 
wall. The atypical cells infiltrating the vessel wall are positive for CD20 and EBER. 
The background consists primarily of numerous CD3-positive cells without atypia (B: 
HE, CD20, CD3, EBER, ×200).  
 
Figure 5. Pathologic findings of large cell-rich EBVMCU 
A gingival ulcer of an 85-year-old female resembling DLBCL (Case No. 27). The lesion 
shows a monomorphic and dense proliferation of atypical large lymphoid cells. In situ 
hybridization shows atypical cells positive for EBER. (HE, EBER, ×400) 
 
Figure 6. Pathologic findings of CHL-like EBVMCU 
A tonsillar ulcer of an 83-year-old male undergoing methotrexate treatment (Case No. 
26). (A) Lymphoid cells infiltration with epithelioid granuloma observe under the ulcer 
(×100). (B) This lesion includes small to large sized atypical lymphoid cells and many 
HRS cells with epithelioid granuloma (×200). (C) Hodgkin cell. (D) Reed-Sternberg 
cell with epithelioid cells. The HRS cells and other polymorphous atypical lymphoid 
cells are positive for EBER. The HRS cells are also positive for CD30 (C, D, CD30, ×
400, EBER, ×200). 
 
Figure 7. Pathologic findings of MALT lymphoma-like EBVMCU 
A lingual ulcer in a 66-year-old female undergoing methotrexate treatment (Case No. 
14). (A) This lesion shows ulceration and dense lymphoid cell proliferation (×40). (B) 
The atypical lymphoid cells show centrocytic-like feature with plasmacytic 
differentiation proliferating in the expanded interfollicular zone (×100). (C) Atypical 
plasmacytic cells with Russell bodies are seen (HE). The atypical lymphoid cells are 
positive for EBER. (EBER, ×400) 
 
Table 1 Clinical and pathological findings of patients with Epstein-Barr virus-positive mucocutaneous ulcer 
Case 
No. 




















1 71 M Tonsil IS (MTX for RA therapy) Reduced IS N.D. N.D. 5500 897 12 3.9 Large － YES CR 109 
2 66 M Tonsil IS (MTX for RA therapy) Reduced IS 2786 209 2700 864 9.8 4.1 Large － YES PR 101 
3 61 F Nasal 
cavity 
IS (MTX for RA therapy) Reduced IS N.D. 173 N.D. N.D. N.D. N.D. Large ＋ YES CR 100 
4 91 M Gingiva IS (MTX for RA therapy) R-THPCOP N.D. 203 5550 1249 11.8 4.1 CHL ＋ N.D. N.D. 26 
5 80 F Nasal 
cavity 
IS (MTX for RA therapy) Reduced IS, 
R-THPCOP 
N.D. N.D. N.D. N.D. N.D. N.D. Large － NO CR 63 
6 80 M Gingiva Age N.D. N.D. N.D. N.D. N.D. N.D. N.D. Poly － N.D. N.D. N.D. 
7 69 M Gingiva Age R-CHOP 263 151 8100 2236 13.3 4.1 MALT － NO CR 56 
8 81 M Oral 
cavity 
IS (MTX for RA therapy) Reduced IS, 
R-THPCOP 
477 269 7990 320 11.2 3.6 Large ＋ NO CR 28 
9 79 M Angle of 
mouth 
IS (Hydroxycarbamide for 
polycythemia) 
Reduced IS 493 397 10570 423 10.9 3.6 Poly － YES PR 7 
10 73 M Tonsil Age N.D. 851 249 4250 1305 12.9 4.3 Poly － N.D. N.D. 49 
11 73 F Oral 
cavity 
IS (MTX for RA therapy) Reduced IS N.D. 286 4450 979 10.9 4.2 CHL － YES CR 34 
12 74 F Nasophar
ynx 
IS (MTX for RA therapy) Reduced IS 1000 277 11600 1508 10.7 3.6 Poly － YES CR 19 
13 65 F Tonsil IS (MTX for RA therapy) Reduced IS 551 211 5200 2132 10.8 3.8 CHL － YES CR 1 
14 66 F Tongue IS (MTX for RA therapy) Reduced IS 373 152 4800 629 10.7 4.1 MALT － YES PR 23 
15 70 F Gingiva IS (MTX for RA therapy) Reduced IS 744 195 7500 975 11.5 3.4 Large ＋ YES CR 33 
16 76 F Gingiva IS (MTX for RA therapy) Reduced IS 894 206 7500 1875 12.8 N.D. Poly ＋ YES CR 33 
17 71 M Skin of 
leg 
IS (MTX for PMR 
therapy) 
Reduced IS 466 273 4110 1278 12.5 4.3 Poly － YES CR 21 
18 74 F Tonsil IS (MTX for RA therapy) Reduced IS N.D. 281 N.D. N.D. N.D. N.D. Poly ＋ YES CR 21 
19 78 F Gingiva IS (MTX and TAC for RA 
therapy) 
Reduced IS N.D. 236 4830 1159 10.2 3.5 Poly － YES PR 10 
20 75 F Tongue IS (MTX for RA therapy) Reduced IS N.D. 260 4060 889 11 3.5 Poly ＋ YES PR 11 
21 78 M Oral 
cavity 
IS (MTX for RA therapy) Reduced IS 628 185 6310 1660 13.4 3.9 Poly ＋ YES PR 3 
22 72 F Skin of 
leg 
IS (MTX for RA therapy) Reduced IS 1157 327 4150 506 11.3 3.1 Poly ＋ YES PR 2 
23 70 F Tonsil IS (MTX for RA therapy) Reduced IS 1771 221 4800 336 11.6 3.4 Poly － N.D. N.D. N.D. 
24 67 M Pharynx IS (MTX for RA therapy) Reduced IS 666 200 6950 514 12 3.8 Poly － YES CR 26 
25 81 M Pharynx IS (MTX for RA therapy) Reduced IS N.D. N.D. N.D. N.D. N.D. N.D. Poly － YES CR 13 
26 83 M Tonsil IS (MTX for RA therapy) N.D. 655 154 7090 N.D. 12.7 N.D. CHL － N.D. N.D. N.D. 
27 85 F Gingiva IS (MTX for RA therapy) Reduced IS N.D. N.D. N.D. N.D. N.D. N.D. Large ＋ YES CR 15 
28 71 F Gingiva IS (MTX for RA therapy) Reduced IS 385 200 6710 570 13.7 4.6 Poly ＋ N.D. N.D. N.D. 
29 67 M Gingiva IS (MTX for RA therapy) Reduced IS N.D. N.D. N.D. N.D. N.D. N.D. Poly ＋ YES CR 11 
30 65 F Gingiva IS (MTX for RA therapy) Reduced IS 500 233 8800 1602 12.5 4.3 Poly ＋ YES CR 3 
31 54 M Buccal 
mucosa 
IS (MTX for RA therapy) Reduced IS 648 212 7560 1875 11.4 3.8 Poly － YES PR 1 
32 67 F Gingiva IS (MTX for RA therapy) Reduced IS 270 225 8420 1372 14.3 4.2 MALT － YES CR 2 
33 75 M Gingiva IS (MTX for RA therapy) Reduced IS 1224 180 6840 903 11.6 2.9 Poly － YES CR 5 
34 86 F Gingiva IS (MTX for RA therapy) Reduced IS 921 187 7000 3983 9.4 3.5 Poly ＋ YES CR 4 
CHL, classic Hodgkin lymphoma-like feature; CR, complete remission; Large, large cell rich feature; F, female; IS, immunosuppression; M, male; MALT, mucosa-associated lymphoid tissue lymphoma-like feature; MTX, 
methotrexate; N.D., not done; PMR, polymyalgia rheumatica; Poly, polymorphous feature; PR, partial response; RA, rheumatoid arthritis; TAC, tacrolimus; UD, undetectable. 
 
Table 2 Comparison of laboratory findings in EBVMCU, EBV-positive DLBCL and EBV-negative DLBCL 
EBVMCU EBV-positive DLBCL EBV-negative DLBCL 
  n=34 n=24 n=25 







































Albumin (g/dl) 3.8 (2.9-4.6) 3.3 (2.0-4.9) 3.9 (2.8-4.4) 





sIL-2R: soluble interleukin 2 receptor, LDH: lactate dehydrogenase, WBC: white blood cell count 
 
Table 3 Comparison of molecular findings in EBVMCU, EBV-positive DLBCL and EBV-negative DLBCL 
EBVMCU EBV-positive DLBCL EBV-negative DLBCL 
  (n=34) (n=24) (n=25) 
IGH (FR2) clonality 
  mono/oligo 







    
IGH (FR3) clonality 
  mono/oligo 







    
IGH clonality 
  mono/oligo 







  P=0.377 P=0.280 
    
IGK clonality 
  mono/oligo 
  poly 
10 (40%) 
15 (60%) 
Not done Not done 
    
IGL clonality 
  mono/oligo 
  poly 
6 (86%) 
1 (14%) 
Not done Not done 
    
TCR clonality 
  mono/oligo 







  P=0.060 P=0.176 
mono: monoclonal, oligo: oligoclonal, poly: polyclonal 
 







